VWVivian Hsing-Chun Wang

Vivian Hsing-Chun Wang

*This is an algorithmically generated author record based on publicly available information.

Vivian Hsing-Chun Wang has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • José A. Pagán

    New York University School of Global Public Health, 708 Broadway, 7th Floor, New York, NY 10003, United States

    4 shared publications
  • Donglan Zhang

    Division of Health Services Research, Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY, USA

    3 shared publications
  • José Antonio Pagán

    Affiliation School of Global Public Health, New York University, New York, New York, United States of America

    3 shared publications
  • Anand Rajan

    Department of Foundations of Medicine, Center for Population Health and Health Services Research, New York University Grossman Long Island School of Medicine , Mineola, NY 11501

    2 shared publications
  • Donglan Zhang

    Center for Population Health and Health Services Research, New York University Grossman Long Island School of Medicine, 101 Mineola Blvd, Mineola, NY, 11501, USA

    2 shared publications
  • Jasmin Divers

    Center for Population Health and Health Services Research, Department of Foundations of Medicine, New York University Grossman Long Island School of Medicine 1 , Mineola, NY

    2 shared publications

Latest Publications

  • Open Access

    Concordance with the MIND diet is associated with lower subsequent epigenetic aging

    by Vivian Hsing-Chun Wang, Jordan Weiss, Yian Y Gu, Jeannette M. Beasley, Emily Johnston, Arjun Masurkar, Daniel Wronski, Donglan S Zhang

    Healthy dietary patterns may influence biological aging, but prospective evidence for the MediterraneanDASH Intervention for Neurodegenerative Delay (MIND) diet is limited. We linked 2013 dietary data to 2016 DNA methylation measures in 1,740 Health and Retirement Study participants. Per 1-s.d. higher MIND score, adjusted differences were -0.4 years for PhenoAge acceleration (95% CI -0.8 to -0.1), -0.3 years for GrimAge acceleration (-0.5 to -0.1) and -0.0054 for methylation Pace of Aging (-0.0098 to -0.0010); all false-discovery-rate q≤0.026. Associations persisted after body-mass-index adjustment and selection weighting. Targeted maximum likelihood estimates were concordant with the conventional models, whereas causal forests evaluated in held-out and repeated-split samples found no reproducible evidence that specific subgroups of participants benefited more than others. Greater MIND adherence was associated with lower subsequent epigenetic aging across complementary measures, supporting molecular aging as an intermediate phenotype for diet-aging research.

  • What next? Sustaining anti-obesity pharmacotherapy success through metabolic maintenance

    by Raymond G. Lau, Vivian Hsing-Chun Wang, Thomas Gatto, Lauren Perrone, Juan Batista, Niti Rajpal, Stanislaw Klek, Nastassia DeSouza, Michelle Lorge, Donglan Stacy Zhang

  • New York state's paid family leave improved postpartum health care among women with hypertensive disorders in pregnancy

    by Donglan Zhang, Jun Soo Lee, Elena V Kuklina, Lisa M Pollack, Sandra L Jackson, Nicole L Therrien, Kai Hong, Xiaobei Dong, Anand Rajan, Wendy L Kinzler, et al.

    Introduction: Hypertensive disorders in pregnancy, including chronic and pregnancy-induced hypertension, pose significant risks to maternal health. This study evaluated the association of New York State (NYS)'s Paid Family Leave (PFL) law, implemented in 2018, with postpartum healthcare utilization among women with hypertensive disorders in pregnancy. Methods: Using commercial claims data (2017-2022) for 312 470 employed women aged 15-45 years with live births, we assessed postpartum outpatient visits, hospital admissions, and medication adherence. Results: The PFL law was associated with a 3.7%-point increase in outpatient visits within 7 days postpartum for women with chronic hypertension (from 25.9% to 29.6% in NYS, P < 0.001) and an 8.6%-point increase for women with pregnancy-induced hypertension (from 26.3% to 35.0%) in NYS, P < 0.001). The PFL law was associated with a 1.5%-point reduction in inpatient admissions for women with chronic hypertension (from 3.6% to 2.1% in NYS, P < 0.001), and a 7.1%-point improvement in antihypertensive medication adherence for women with chronic hypertension (from 26.6% to 33.8% in NYS, P < 0.001). Conclusion: Study findings suggest that PFL laws may enhance postpartum hypertension management, providing useful insights for policymakers aiming to improve maternal health outcomes through workplace policies.


  • Open Access

    Time to use large-scale biobank databases in health policy and public health research

    by José A Pagán, Vivian Hsing-Chun Wang, Hannah Sur

    Large-scale biobank databases link data from thousands of participants and multiple sources such as electronic health records, surveys, imaging, and biomarkers. These data infrastructure research initiatives have the potential to inform health care and public health solutions that can address the needs of different populations, facilitate cross-sector collaboration, and improve the overall responsiveness of health care and public health systems. Despite this potential, large-scale biobanks are severely underutilized to answer health policy and public health research questions. Part of the reason is that information available in these data sources is usually collected for purposes such as improving health care within an integrated health care delivery system or advancing precision medicine. Still, the depth and breadth of these data collection efforts around the world together with advances in data science and artificial intelligence provide new opportunities to answer important health policy and public health questions using large-scale biobank data.


  • Experiences of patient-provider concordance in healthcare among All of Us participants, 2017–2023

    by Julie Holm, Adolfo Cuevas, Vivian Hsing-Chun Wang, José A. Pagán, Diana Silver


  • Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes

    by Donglan Zhang, Nihan Gencerliler, Amrita Mukhopadhyay, Saul Blecker, Morgan E. Grams, Davene R. Wright, Vivian Hsing-Chun Wang, Anand Rajan, Eisha Butt, Jung-Im Shin, et al.

    OBJECTIVE: To examine the associations between patient out-of-pocket (OOP) costs and nonadherence to glucagon-like peptide 1 receptor agonists (GLP-1RA), and the consequent impact on adverse outcomes, including hospitalizations and emergency department (ED) visits. RESEARCH DESIGN AND METHODS: This retrospective cohort study used MarketScan Commercial data (2016–2021). The cohort included nonpregnant adults aged 18–64 years with type 2 diabetes who initiated GLP-1RA therapy. Participants were continuously enrolled in the same private insurance plan for 6 months before the prescription date and 1 year thereafter. Exposures included average first 30-day OOP costs for GLP-1RA, categorized into quartiles (lowest [Q1] to highest [Q4]). Primary outcomes were the annual proportion of days covered (PDC) for GLP-1RA and nonadherence, defined as PDC <0.8. Secondary outcomes included diabetes-related and all-cause hospitalizations and ED visits 1 year after GLP-1RA initiation. RESULTS: Among 61,907 adults who initiated GLP-1RA, higher 30-day OOP costs were associated with decreased adherence. Patients in the highest OOP cost quartile (Q4: $80–$3,375) had significantly higher odds of nonadherence (odds ratio [OR] 1.25; 95% CI 1.19–1.31) compared with those in Q1 ($0–$21). Nonadherence was linked to increased incidence rates of diabetes-related hospitalizations or ED visits (incidence rate ratio [IRR] 1.86; 95% CI 1.43–2.42), cumulative length of hospitalization (IRR 1.56; 95% CI 1.41–1.72), all-cause ED visits (IRR 1.38; 95% CI 1.32–1.45), and increased ED-related costs ($69.81, 95% CI $53.54–$86.08). CONCLUSIONS: Higher OOP costs for GLP-1RA were associated with reduced adherence and increased rates of adverse outcomes among patients with type 2 diabetes.


  • Racial and ethnic differences in the receipt of continuous positive airway pressure treatment for obstructive sleep apnea

    by Vivian Hsing-Chun Wang, Yike Li, David T. Kent, José A. Pagán, Milla Arabadjian, Jasmin Divers, Donglan Zhang


  • Use of calibration to improve the precision of estimates obtained from All of Us data

    by Vivian Hsing-Chun Wang, Julie Holm, José A Pagán

    To highlight the use of calibration weighting to improve the precision of estimates obtained from All of Us data and increase the return of value to communities from the All of Us Research Program. We used All of Us (2017-2022) data and raking to obtain prevalence estimates in two examples: discrimination in medical settings (N = 41 875) and food insecurity (N = 82 266). Weights were constructed using known population proportions (age, sex, race/ethnicity, region of residence, annual household income, and home ownership) from the 2020 National Health Interview Survey. About 37% of adults experienced discrimination in a medical setting. About 20% of adults who had not seen a doctor reported being food insecure compared with 14% of adults who regularly saw a doctor. Calibration using raking is cost-effective and may lead to more precise estimates when analyzing All of Us data.


  • Discrimination in Medical Settings across Populations: Evidence From the All of Us Research Program

    by Vivian Hsing-Chun Wang, Adolfo G. Cuevas, Onome Henry Osokpo, Ji Eun Chang, Donglan Zhang, Anqing Hu, Jeongwook Yun, Adaora Lee, Shilei Du, David R. Williams, et al.


  • Open Access

    Accelerating integration of tobacco use treatment in the context of lung cancer screening: Relevance and application of implementation science to achieving policy and practice

    by Donna Shelley, Vivian Hsing-Chun Wang, Kathryn Taylor, Randi Williams, Benjamin Toll, Alana Rojewski, Kristie L Foley, Nancy Rigotti, Jamie S Ostroff

    Based on the findings from the National Lung Screening Trial, the U.S. Preventive Services Task Force recommends annual low dose computed tomography (LDCT) lung cancer screening (LCS) among high-risk adults. Approximately 54% of individuals seeking LCS report current cigarette smoking. Effective smoking cessation interventions, offered at the time of LCS, enhances the health benefits of screening that are attributable to reductions in lung cancer overall and tobacco-related mortality. Considering these data, the Centers for Medicare & Medicaid Services’ (CMS) 2015 decision to cover LCS with LDCT required that radiology imaging facilities make tobacco cessation interventions available for people who smoke. In February 2022, CMS reversed their 2015 coverage requirement for delivering tobacco use treatment at the time of LDCT; CMS retained the requirement for counseling during the shared decision-making visit prior to the exam. The policy change does not diminish the importance of offering high-quality tobacco cessation services in conjunction with routine LDCT for LCS. However, LCS programs face a range of barriers to implementing tobacco use treatment in their settings. As a result, implementation has lagged. Closing the “evidence to practice” gap is the focus of implementation science, a field that offers a set of rigorous methods and a systematic approach to identifying and overcoming contextual barriers to implementing evidence-based guidelines in a range of clinical settings. In this paper, we describe how implementation science frameworks and methods can be used to help guide LCS programs in their efforts to integrate tobacco use treatment and discuss policy changes needed to further facilitate the delivery of TUT as an essential component of the LCS process.